192 related articles for article (PubMed ID: 36544075)
1. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
3. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
4. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
Dubberke ER; Lee CH; Orenstein R; Khanna S; Hecht G; Gerding DN
Clin Infect Dis; 2018 Sep; 67(8):1198-1204. PubMed ID: 29617739
[TBL] [Abstract][Full Text] [Related]
5. Safety of fecal microbiota, live-jslm (REBYOTA
Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
[TBL] [Abstract][Full Text] [Related]
6. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent
Tillotson G; Archbald-Pannone L; Johnson S; Ng S; Ando M; Harvey A; Bancke L; Feuerstadt P
Open Forum Infect Dis; 2023 Jan; 10(1):ofac703. PubMed ID: 36686631
[TBL] [Abstract][Full Text] [Related]
9. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
J Clin Gastroenterol; 2023 Nov; ():. PubMed ID: 38019088
[TBL] [Abstract][Full Text] [Related]
10. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.
Orenstein R; Dubberke E; Hardi R; Ray A; Mullane K; Pardi DS; Ramesh MS;
Clin Infect Dis; 2016 Mar; 62(5):596-602. PubMed ID: 26565008
[TBL] [Abstract][Full Text] [Related]
11. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
12. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.
Kwak S; Choi J; Hink T; Reske KA; Blount K; Jones C; Bost MH; Sun X; Burnham CD; Dubberke ER; Dantas G;
Microbiome; 2020 Aug; 8(1):125. PubMed ID: 32862830
[TBL] [Abstract][Full Text] [Related]
13. Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic.
Blount KF; Shannon WD; Deych E; Jones C
Open Forum Infect Dis; 2019 Apr; 6(4):ofz095. PubMed ID: 31024971
[TBL] [Abstract][Full Text] [Related]
14. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
15. Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent
Papazyan R; Ferdyan N; Srinivasan K; Gonzalez C; Shannon WD; Blount K; Fuchs BC
Microorganisms; 2023 Jan; 11(1):. PubMed ID: 36677428
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
17. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
[TBL] [Abstract][Full Text] [Related]
18. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection.
Feuerstadt P; Allegretti JR; Dubberke ER; Guo A; Harvey A; Yang M; Garcia-Horton V; Fillbrunn M; Tillotson G; Bancke LL; LaPlante K; Garey KW; Khanna S
Infect Dis Ther; 2024 Jan; 13(1):221-236. PubMed ID: 38236515
[TBL] [Abstract][Full Text] [Related]
20. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
